NYMC Faculty Publications
Sustained Treatment Response and Global Improvements With Long-Term Valbenazine in Patients With Tardive Dyskinesia
Author Type(s)
Faculty
DOI
10.1097/JCP.0000000000001860
Journal Title
Journal of Clinical Psychopharmacology
First Page
353
Last Page
361
Document Type
Article
Publication Date
7-1-2024
Department
Psychiatry and Behavioral Sciences
Abstract
PURPOSE/BACKGROUND: Using data from KINECT® 4, a phase 3, 48-week study of valbenazine, post hoc analyses were conducted to assess long-term outcomes that are relevant to the real-world management of tardive dyskinesia (TD). METHODS/PROCEDURES: Post hoc analyses of the participants of the KINECT 4 study who completed 48 weeks of open-label valbenazine (40 or 80 mg) treatment were conducted. Valbenazine effects on TD were evaluated using the Abnormal Involuntary Movement Scale (AIMS), Clinical Global Impression of Change-TD (CGI-TD), and Patient Global Impression of Change (PGIC). FINDINGS/RESULTS: Of 103 participants completing 48 weeks of treatment, 55% experienced clinically meaningful improvement (defined as ≥2-point reduction in AIMS total score [sum of items 1 - 7, evaluated by site raters]) by week 4; at week 48, 97% met this threshold. The percentage of completers who achieved AIMS total score response thresholds of ≥10% to ≥90% increased over time, with 86% of completers reaching ≥50% improvement. Of the 40 (39%) completers with AIMS ≥50% response at week 8, 38 (95%) sustained this response at week 48; 81% of those who did not meet this threshold at week 8 had achieved it by week 48. At week 48, more than 85% of completers achieved CGI-TD and PGIC ratings of "much improved" or "very much improved." IMPLICATIONS/CONCLUSIONS: The majority of participants who completed 48 weeks of treatment with once-daily valbenazine experienced substantial clinically meaningful and sustained TD improvements. These findings indicate that valbenazine can be a highly effective long-term treatment in patients with TD.
Recommended Citation
Correll, C. U., Citrome, L., Singer, C., Lindenmayer, J., Zinger, C., Liang, G., Dunayevich, E., & Marder, S. R. (2024). Sustained Treatment Response and Global Improvements With Long-Term Valbenazine in Patients With Tardive Dyskinesia. Journal of Clinical Psychopharmacology, 44 (4), 353-361. https://doi.org/10.1097/JCP.0000000000001860